Crestor Safety Data Will Come From Five New Studies, AstraZeneca Says

The pharmacoepidemiology studies will compare Crestor’s safety and efficacy to that of other marketed statins. The results may help AstraZeneca revive Crestor’s market share, which dropped following the November Senate testimony of an FDA drug safety officer, who said the statin has unresolved safety issues.